Menu

Infographic: The Brain on Psychedelics

Understanding how hallucinogenic drugs affect different neural networks could shed light on their therapeutic potential.

Aug 31, 2017
Diana Kwon

© CATHERINE DELPHIA

Key brain areas involved in the effects of psychedelic drugs are located in the default mode network (DMN), which is more active at rest than when attention is focused on the external environment. Neuroscientists first discovered this network while scanning participants’ brains at rest: rather than a decrease in activity across the brain, they found that activity in some regions was actually higher when people were not engaged in a goal-directed task. Over the years, researchers have linked the DMN to a variety of functions, including autobiographical recollection, mind wandering, and processing self-related information.

Key hubs of the DMN include the posterior cingulate cortex (PCC), the medial prefrontal cortex (mPFC), and the posterior inferior parietal lobule (pIPL). Through neuroimaging, researchers have discovered that psychedelic drug use decreases activity in some of these brain areas, and also reduces connectivity within the DMN.

Neuroimaging studies have also shown that connectivity between brain networks is increased when psychedelics are administered. For example, the DMN; the salience network, which helps identify behaviorally relevant information; and the frontoparietal network, known to be involved in attentional control and conscious awareness, all show stronger connections to each other. Researchers believe that this increased crosstalk throughout the brain may play a key role in the drugs’ effects.

© CATHERINE DELPHIA

Psychedelics’ Anti-inflammatory Effects

Scientists have discovered that a number of psychedelics can reduce inflammation throughout the body. Animal studies with one of these drugs, DOI, which is an especially potent anti-inflammatory compound, are starting to reveal the mechanism behind these effects. According to one hypothesis, DOI binds to and activates the serotonin 2A (5-HT2A) receptor to recruit protein kinase C (PKC). This is thought to block the downstream effects of the binding of tumor necrosis factor-alpha (TNF-α) to its receptor (TNFR), which is known to initiate a signaling cascade that promotes the transcription of proinflammatory genes.

© CATHERINE DELPHIA
Read the full story.

August 2018

Conscious Rodents?

The complex ethics of transplanting human brain organoids into rats and mice

Marketplace

Sponsored Product Updates

New Compact Refrigerators Designed for Secure and Sustainable Clinical Storage

New Compact Refrigerators Designed for Secure and Sustainable Clinical Storage

A new series of compact refrigerators has been specifically developed to address the need of clinical laboratories and patient care facilities for cold storage equipment that enable secure and energy-efficient storage of vaccines, medicines, lab kits and breast milk, while offering quiet operation and a small footprint.

New 25 ml divided reservoir offers lowest dead volume on the market

New 25 ml divided reservoir offers lowest dead volume on the market

INTEGRA has expanded its Clear Advantage™ product family to include a divided reservoir, offering 5 and 10 ml volumes side-by-side, while still nesting comfortably in the company’s standard 25 ml reusable, sturdy base. A combination of design and innovation offers a pipetting experience with less reagent and plastic waste, and the lowest dead volume on the market.

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.

New England Biolabs® Launches NEBNext Direct® Custom Ready Panels for Efficient Targeted Re-sequencing

New England Biolabs® Launches NEBNext Direct® Custom Ready Panels for Efficient Targeted Re-sequencing

New England Biolabs (NEB®) today announced the launch of the NEBNext Direct Custom Ready Panels. The new panels — coupled with the proprietary NEBNext Direct target enrichment technology — enable the rapid development and deployment of a customized target enrichment panel by allowing users to select from an extensive library of genes to produce sequencing data with high specificity and coverage uniformity.